In conventional symptomatic AD, the transient suppression of the neuronal ISR combined concurrently with the activation of BACE1 and/or BACE2 would stop the progression of the disease and prevent its recurrence within the remaining lifespan of the treated patient. The gene discussed is BACE2; the disease is Alzheimer disease.